Ultivue
Ultivue is a Cambridge-based spatial biology company that develops the InSituPlex multiplexed immunofluorescence platform for spatial proteomics in tissue. Following its announced merger with Vizgen, it offers an integrated spatial multiomics portfolio spanning MERFISH transcriptomics, proteomics, and AI-driven analysis, serving pharma, biotech, and academic researchers in immuno-oncology and companion diagnostics.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ultivue does
Ultivue, Inc. is a privately held biotechnology company founded in 2015 and headquartered in Cambridge, Massachusetts, operating in the spatial biology market. The company's core technology is InSituPlex, a multiplexed immunofluorescence assay that enables spatial proteomic analysis of tissue, allowing researchers to map multiple protein biomarkers at single-cell resolution within intact tissue samples, including FFPE specimens. Its primary customer base is pharmaceutical and biotechnology research organizations engaged in immuno-oncology biomarker discovery and companion diagnostics development, where the platform is positioned to identify patient sub-populations that respond to immune checkpoint inhibitors and adoptive T-cell therapies.
Ultivue announced a merger with Vizgen to unify spatial biology capabilities, integrating Vizgen's MERFISH spatial transcriptomics platform (delivered via the MERSCOPE Ultra instrument) with Ultivue's InSituPlex protein assays. The combined portfolio spans instruments, reagents and consumables, core and custom biomarker panels (OmniVUE and U-VUE), and AI-enhanced analysis software (STARVUE and MERSCOPE Vizualizer), supported by a global footprint of 200+ MERSCOPE platforms and 400+ peer-reviewed MERFISH publications. Applications explicitly span neuroscience, oncology, immunology, and cell atlasing.
The company's revenue mechanics reflect a life sciences tools model, combining instrument sales (MERSCOPE Ultra), recurring consumables and reagents, custom and catalog biomarker panels, and service offerings (Spatial Transcriptomics and Spatial Omics Services). The company is venture-backed, with disclosed funding rounds totaling roughly $110M across Series A through a 2021 Series C (Northpond Ventures, ARCH Venture Partners, Applied Ventures, among others), and a 2024 SEC Form D exempt offering targeting an additional ~$15M of capital. Pricing is not publicly disclosed. The company has 51–100 employees and remains privately held, with no public ticker.
Ultivue firmographics
Firmographics- Name
- Ultivue
- Legal name
- Ultivue, Inc.
- Website
- https://ultivue.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Ultivue is a Cambridge-based spatial biology company that develops the InSituPlex multiplexed immunofluorescence platform for spatial proteomics in tissue. Following its announced merger with Vizgen, it offers an integrated spatial multiomics portfolio spanning MERFISH transcriptomics, proteomics, and AI-driven analysis, serving pharma, biotech, and academic researchers in immuno-oncology and companion diagnostics.
- Ownership category
- akta.pro rank
Ultivue industry classification
Industry- Product category
- Spatial Biology Instruments and Assays
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)
- akta.pro secondary industries
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
Keywords
Where Ultivue is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ultivue business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Ultivue product offering
Product offeringCore offering
Ultivue develops and sells the InSituPlex multiplexed immunofluorescence assay platform for spatial proteomics, enabling single-cell, in-situ quantification of multiple protein biomarkers in tissue samples including FFPE. Following its announced merger with Vizgen, the combined company also offers MERFISH-based spatial transcriptomics on the MERSCOPE Ultra instrument, custom and core biomarker panels, STARVUE analysis software, and contract spatial omics services for pharmaceutical and academic researchers.
Product overview
Ultivue is a biotechnology company incorporated in Delaware and based in Cambridge, Massachusetts, operating in the spatial biology market. According to a market report, Ultivue announced a merger with Vizgen to unify their spatial biology capabilities. No specific product names, modules, or product architecture details were available in the provided source data.
Differentiator
Problem solved
Functional benefit
Products and services
- InSituPlex Multiplexed Immunofluorescence Assays Pathology-grade multiplexed protein detection assays for FFPE tissue, enabling simultaneous quantification of multiple biomarkers at single-cell and spatial resolution; intended for pharmaceutical and biotech immuno-oncology researchers and clinical laboratories.
- MERSCOPE Ultra Spatial Transcriptomics Platform Instrument platform for spatial transcriptomics using MERFISH 2.0 chemistry, providing single-cell in-situ RNA quantification across large tissue areas; targeted at pharma, biotech, and academic translational researchers.
- MERSCOPE Vizualizer Software Visualization and analysis software for spatial transcriptomics datasets, enabling researchers to explore single-cell RNA maps generated on MERSCOPE instruments.
- Core Biomarker Panels (OmniVUE) Pre-validated multiplexed biomarker panels for InSituPlex spatial proteomics, providing reproducible, FFPE-ready, AI-enhanced analytics for common immuno-oncology and tumor microenvironment targets.
- Custom Biomarker Panels (U-VUE) Customer-defined multiplexed biomarker panels for InSituPlex, allowing researchers to design sensitive, reproducible, FFPE-ready assays for their specific targets of interest.
- STARVUE Single-Cell Spatial Analysis Software AI-driven single-cell and spatial analysis software for multiomics datasets, supporting interpretation of MERFISH and InSituPlex readouts.
- Gene Panels Catalog and configurable gene panels for MERFISH-based spatial transcriptomics, used with the MERSCOPE platform to profile RNA targets in tissue.
- Reagents and Consumables Reagents, kits, and consumables required to run MERSCOPE spatial transcriptomics workflows and InSituPlex spatial proteomics assays, sold as part of the instrument-and-consumable business model.
- Spatial Transcriptomics Services Service offering where the company performs spatial transcriptomics experiments and analysis on customer samples using MERFISH 2.0 and supporting pipelines, delivering reproducible RNA readouts and a concise report.
- Spatial Proteomics Assay Development Services Custom assay development and spatial proteomics services in which the company designs and runs InSituPlex assays for customers, including biomarker panel design and validation.
Companies that use Ultivue
Customer profileSegments1 record
Ideal customer profiles1 record
Ultivue technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Ultivue partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- VizgenflagshipVizgen and Ultivue announced a merger to unify their spatial biology capabilities. The combined entity will integrate Vizgen's MERFISH spatial transcriptomics platform with Ultivue's InSituPlex multiplexed immunofluorescence technology to create a comprehensive spatial multiomics offering.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Ultivue competitors and assessment
Company assessmentEmerging players
- Standard BioTools (formerly Fluidigm): Standard BioTools offers the Hyperion imaging mass cytometry system for highly multiplexed tissue imaging, an alternative spatial proteomics modality competing for translational research budgets alongside InSituPlex.
- Resolve Biosciences: Resolve Biosciences develops Molecular Cartography single-cell spatial transcriptomics for subcellular resolution, representing an emerging competitor in the same spatial biology market as Ultivue/Vizgen.
- Rebus Biosystems: Rebus Biosystems offers the Rebus Esper spatial omics platform with single-molecule resolution, targeting similar translational and pharma research customers with an alternative spatial transcriptomics approach.
- Ionpath (now part of Standard BioTools): Ionpath develops MIBI (multiplexed ion beam imaging) for high-plex spatial proteomics, an emerging technology alternative that competes for translational immuno-oncology and pharma research customers alongside InSituPlex.
Direct peers
- 10x Genomics: 10x Genomics offers Visium and Xenium spatial transcriptomics platforms alongside Chromium single-cell products, directly competing in the same spatial biology market as Ultivue and Vizgen for pharma, translational, and academic customers.
- Vizgen: Vizgen develops MERFISH-based spatial transcriptomics platforms (MERSCOPE) and is now merging with Ultivue to form an integrated spatial multiomics company. Direct overlap in spatial biology tools serving translational and pharma research customers.
- Akoya Biosciences: Akoya Biosciences offers the PhenoCycler (CODEX) multiplexed immunofluorescence platform and PhenoImager HT, directly competing with Ultivue's InSituPlex in spatial proteomics for immuno-oncology and translational research.
- Lunaphore (acquired by Bio-Techne): Lunaphore's COMET multiplexed staining platform is a direct competitor to Ultivue's InSituPlex for automated, high-throughput multiplexed tissue biomarker analysis in translational and clinical research labs.
Broad incumbents
- Bio-Techne: Bio-Techne provides RNAscope in situ hybridization and the GeoMx digital spatial profiling platform via its Diagnostics & Spatial Biology segment, competing with Ultivue in tissue-based biomarker analysis for research and clinical applications.
- Bruker (acquired NanoString): Bruker acquired NanoString Technologies and now sells the CosMx SMI spatial molecular imager alongside a broad life-science instrument portfolio, making it a scaled incumbent competitor in spatial transcriptomics and proteomics.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key highlights6 records
Customer concentration
Ultivue social profiles
Digital presenceUltivue financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ultivue leadership team
Management profileNumber of profiles
Profiles5 records
Ultivue funding detail
Funding detailFunding overview
Funding rounds6 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ultivue M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ultivue
What does Ultivue do?
Ultivue develops and sells the InSituPlex multiplexed immunofluorescence assay platform for spatial proteomics, enabling single-cell, in-situ quantification of multiple protein biomarkers in tissue samples including FFPE. Following its announced merger with Vizgen, the combined company also offers MERFISH-based spatial transcriptomics on the MERSCOPE Ultra instrument, custom and core biomarker panels, STARVUE analysis software, and contract spatial omics services for pharmaceutical and academic researchers.
Is Ultivue a public or private company?
Ultivue is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ultivue founded?
Ultivue was founded in 2015. It employs 51 to 100 people.
Where is Ultivue based?
Ultivue is headquartered in Cambridge, United States, in the North America region.
Who are Ultivue's main competitors?
Emerging players on record are Standard BioTools (formerly Fluidigm), Resolve Biosciences, Rebus Biosystems and Ionpath (now part of Standard BioTools). Direct peers are 10x Genomics, Vizgen, Akoya Biosciences and Lunaphore (acquired by Bio-Techne). Broad incumbents are Bio-Techne and Bruker (acquired NanoString).
Does Ultivue have an API?
No public API is recorded for Ultivue.
What industry is Ultivue in?
Ultivue's product category is Spatial Biology Instruments and Assays. Its primary akta.pro industry code is HLAAAMAI, Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 325413 and its SIC code is 2835.